The value of progression-free survival to patients with advanced-stage cancer

Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint

(2011) Sara A. Hurvitz   CANCER TREATMENT REVIEWS

Reasons given by patients for participating, or not, in Phase 1 cancer trials

(2011) S. Catt et al.   EUROPEAN JOURNAL OF CANCER

Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?

(2011) Harold J. Burstein   JOURNAL OF CLINICAL ONCOLOGY

Big Costs for Little Gain in Ovarian Cancer

(2011) Martee L. Hensley   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

(2011) Jeffrey M. Peppercorn et al.   JOURNAL OF CLINICAL ONCOLOGY

Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes

(2011) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

The ethical use of mandatory research biopsies

(2011) Erin M. Olson et al.   Nature Reviews Clinical Oncology

In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer

(2011) S. Verma et al.   ONCOLOGIST

Health-related quality of life and cancer clinical trials

(2011) David Osoba   Therapeutic Advances in Medical Oncology

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

(2010) J. C. Soria et al.   ANNALS OF ONCOLOGY

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

(2010) T. Fojo et al.   CLINICAL CANCER RESEARCH

63 A comparison of physician and patient perceptions of clinically important endpoints in the treatment of Metastatic Breast Cancer (MBC)

(2010) A. Sheik-Yousouf et al.   EJC SUPPLEMENTS

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

(2010) Dawn Odom et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

End-of-Life Discussions, Goal Attainment, and Distress at the End of Life: Predictors and Outcomes of Receipt of Care Consistent With Preferences

(2010) Jennifer W. Mack et al.   JOURNAL OF CLINICAL ONCOLOGY

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial Discussions

(2010) Valerie Jenkins et al.   JOURNAL OF CLINICAL ONCOLOGY

When Are "Positive" Clinical Trials in Oncology Truly Positive?

(2010) A. Ocana et al.   JNCI-Journal of the National Cancer Institute

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

(2009) E. D. Saad et al.   ANNALS OF ONCOLOGY

Patient-reported outcomes in drug safety evaluation

(2009) E. Basch   ANNALS OF ONCOLOGY

Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?

(2009) Pavlo Ohorodnyk et al.   EUROPEAN JOURNAL OF CANCER

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Maintenance therapy in non-small-cell lung cancer

(2009) Thomas E Stinchcombe et al.   LANCET

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

(2009) Tudor Ciuleanu et al.   LANCET

Cancer patient preferences for quality and length of life

(2008) Neal J. Meropol et al.   CANCER

Recommendations for the assessment of progression in randomised cancer treatment trials

(2008) J.E. Dancey et al.   EUROPEAN JOURNAL OF CANCER

Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception

(2008) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?

(2008) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Trials in palliative treatment—have the goal posts been moved?

(2008) Peter Kirkbride et al.   LANCET ONCOLOGY

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

(2008) Aloka Chakravarty et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?

(2007) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY